icon/portfolio-licensing
icon/portfolio-licensing

Developing a robust long-term portfolio, licensing & development strategy is paramount for life sciences companies seeking to gain a competitive advantage in an industry where new innovations and breakthroughs seem to be on the constant horizon. Putnam brings a unique blend of clinical and scientific expertise, innovative business strategy and over three decades of strategic experience to advise on optimal and sustainable portfolio, licensing and development strategies for life sciences clients across the globe.

  • Long term portfolio planning and optimization
  • Therapeutic area landscape evolution analysis planning
  • Technology & asset scans
  • In-licensing/out-licensing due diligence
  • Integrative strategy development that incorporates both legacy and newly acquired assets

Supporting our Portfolio, Licensing & Development Strategy is Functional Expertise in Key Disciplines

Clinical & Scientific Expertise

Understanding the HOW related to clinical asset positioning

Deep Experience & Rigorous Strategic Perspective

Drawing on Deep Expertise and Framing Issues from a STRATEGIC PERSPECTIVE to produce client impact

Patient Opportunity & Forecast Modeling

Quantifying the IMPACT on business opportunity

Projects

  • Therapeutic area landscape evolution analysis and strategic plan development (including development and commercial teams)
  • Technology landscape mapping to inform dev. and BD&L activities
  • Portfolio and therapeutic area strategic prioritizations
  • Cross-portfolio analysis of new delivery/formulation opportunities
  • Biosimilars landscape and opportunity analysis
  • Evaluating strategic investment opportunities
  • Technology & asset scans
  • In-licensing due diligence
  • Out-licensing due diligence
  • Integrative strategy development to incorporate both legacy and newly acquired assets
  • Newly acquired in-line product market strategy gap assessment
  • Lifecycle pricing strategies
  • Value narrative evolution including RWE development and value messaging.
  • Guideline and payer coverage expansion
  • Lifecycle contract optimization
  • Targeted account-level contracting strategy
  • National/Local tender strategy
  • Competitive entry defense
  • Loss-of-Exclusivity (LOE) strategies
  • Parallel trade and international reference pricing management

Putnam Case Example

Goals and Strategic Framework
  • At the outset of this project, Putnam worked closely with the Client team to define the scope of relevant “Rheumatology” diseases based on unmet needs and Client strategic objectives
Evidence & Insight
  • Putnam classified Rheumatology diseases, created a database of hundreds of conditions, and based on internal expert and KOL interviews, selected diseases for in-depth assessment and performed deep dive assessments
Impact
  • At the final step, each disease was rated based on overall commercial opportunity and R&D cost, time and risk for an aspirational product concept, and then subjected to a sensitivity analysis, to guide strategic decision-making
Our Practice Areas
  • icon/value
    Value, Pricing & Access Strategy
  • icon/medical
    Medical & Scientific Affairs Strategy
  • icon/product-strategy
    New Product Strategy
  • icon/portfolio-licensing
    Portfolio Licensing & Development Strategy
  • Established Product & Franchise Strategy
  • Data Strategy
    • Internal Areas of Excellence
  • icon/forecast-model
    Market Research
  • icon/cell-therapy
    Cell + Gene Therapy
  • Data Strategy & Analytics

    • Get in Touch

    We partner with clients to address the most complex challenges facing the life sciences industry. Our carefully designed evidence-based strategies allow us to generate winning insights for our clients all over the globe.

    How can we help you and your team?
    • This field is for validation purposes and should be left unchanged.

    Strategy for the Life Sciences